在角膜新血管化中评估一种新的潜在贝瓦西祖马布生物类似药的评估
Armağan Özgür1, Nilüfer Yeşilırmak2, Mehmet Arda İnan3
1Ankara Bilkent City Hospital, Clinic of Ophthalmology, Ankara, Türkiye.
Turkish journal of ophthalmology
|December 25, 2025
概括
一种新的贝瓦西祖马布生物类似剂在治疗子角膜新血管化 (CNV) 时,表现出与贝瓦西祖马布可比的抗血管效应. 与对照组相比,这两种治疗都显著减少了CNV面积.
科学领域:
- 眼科医生 眼科 眼科
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 角膜新血管化 (CNV) 对视力构成重大威胁.
- 抗VEGF疗法,比如贝瓦齐祖马布,对于控制CNV至关重要.
- 评估生物类似药物对于扩大治疗可用性至关重要.
研究的目的:
- 为了比较贝瓦齐祖马布和一种新的贝瓦齐祖马布生物类似剂 (抗人类VEGF GU01) 在治疗线诱导的子内核病毒中的疗效.
- 评估贝瓦齐祖马布生物类似剂的抗血管性潜力.
主要方法:
- 在子眼中使用丝 sutures诱导角膜新血管化.
- 子接受了平衡盐溶液 (对照剂),贝瓦齐祖马布或贝瓦齐祖马布生物类似剂的亚结合膜注射.
- 在治疗前和治疗后分析角膜图像,以量化CNV区域减少.
主要成果:
- 与对照组相比,贝瓦齐祖马布和贝瓦齐祖马布生物类似剂组的CNV面积显著减少 (分别减少82.2%和83.4%).
- 在贝瓦齐祖马布和生物类似药组之间没有观察到CNV回归率的统计学上显著差异.
- 组织病理学分析证实了观察到的抗血管生成效应.
结论:
- 潜在的贝瓦齐祖马布生物类似物,抗人类VEGF GU01,在治疗角膜新血管化方面与贝瓦齐祖马布一样有效.
- 这一发现支持生物仿制药作为一种可行的治疗选择的潜力.
相关概念视频
01:13Bioequivalence studies: Biowaivers
197
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
197
01:28Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
01:16Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:27Open Angle Glaucoma: Treatment
917
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
917